Molecular pathogenesis of pulmonary arterial hypertension

Journal of Clinical Investigation

Volumn 118, Issue 7, 2008, Pages 2372-2379

  Rabinovitch, Marlene ^a  

^a STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADRENOMEDULLIN; ANTICOAGULANT AGENT; BONE MORPHOGENETIC PROTEIN 4; BONE MORPHOGENETIC PROTEIN RECEPTOR 2; BOSENTAN; CYCLOSPORIN; DICHLOROACETIC ACID; ELASTASE; ELASTASE INHIBITOR; ENDOTHELIAL NITRIC OXIDE SYNTHASE; ENDOTHELIN; ENDOTHELIN A RECEPTOR ANTAGONIST; ENDOTHELIN RECEPTOR ANTAGONIST; FASUDIL; IMATINIB; NITRIC OXIDE; PHOSPHODIESTERASE V INHIBITOR; POTASSIUM CHANNEL; PROSTACYCLIN; RHO KINASE INHIBITOR; ROSIGLITAZONE; SEROTONIN RECEPTOR; SEROTONIN TRANSPORTER; SILDENAFIL; SURVIVIN; THROMBOXANE; TRANSIENT RECEPTOR POTENTIAL CHANNEL 3; VASOACTIVE INTESTINAL POLYPEPTIDE; VASOCONSTRICTOR AGENT; VASODILATOR AGENT;

APOPTOSIS; BLOOD VESSEL WALL; CELL ACTIVITY; CELL PROLIFERATION; CLINICAL STUDY; DISEASE ACTIVITY; DISORDERS OF MITOCHONDRIAL FUNCTIONS; DRUG EFFECT; DRUG MECHANISM; DRUG TARGETING; ENZYME ACTIVITY; EPITHELIUM CELL; EXPERIMENTAL STUDY; FIBROBLAST; GENE MUTATION; GENE THERAPY; GENE TRANSFER; GENETICS; HEART MUSCLE CELL; HEART RIGHT VENTRICLE; HUMAN; HYPOXIA; LUNG ARTERY PRESSURE; LUNG BLOOD FLOW; LUNG BLOOD VESSEL; LUNG CIRCULATION; LUNG VASCULAR RESISTANCE; MOLECULAR DYNAMICS; NONHUMAN; PATHOGENESIS; POTASSIUM CHANNELOPATHY; PRIORITY JOURNAL; PULMONARY ARTERY; PULMONARY HYPERTENSION; REVIEW; SMOOTH MUSCLE FIBER; STEM CELL TRANSPLANTATION; TISSUE REGENERATION; VASCULITIS; VASOCONSTRICTION; VASODILATATION;

ANIMALS; BONE MORPHOGENETIC PROTEIN RECEPTORS, TYPE II; HUMANS; HYPERTENSION, PULMONARY; INFLAMMATION MEDIATORS; ION CHANNELS; LEUKOCYTE ELASTASE; MESENCHYMAL STEM CELLS; MODELS, BIOLOGICAL; VASODILATOR AGENTS;

EID: 46749142123     PISSN: 00219738     EISSN: 15588238     Source Type: Journal    
DOI: 10.1172/JCI33452     Document Type: Review

References (125)

1. Simonneau, G., et al. 2004. Clinical classification of pulmonary hypertension. J. Am. Coll. Cardiol. 43:5S-12S.
2. Humbert, M., et al. 2006. Pulmonary arterial hypertension in France: results from a national registry. Am. J. Respir. Crit. Care Med. 173:1023-1030.
3. Meyrick, B., and Reid, L. 1980. Ultrastructural findings in lung biopsy material from children with congenital heart defects. Am. J. Pathol. 101:527-537.
4. Jones, P.L., Cowan, K.N., andRabinovitch, M. 1997. Tenascin-C, proliferation and subendothelial fibro-nectin in progressive pulmonary vascular disease. Am. J. Pathol. 150:1349-1360.
5. Davie, N.J., et al. 2004. Hypoxia-induced pulmonary artery adventitial remodeling and neovascularization: contribution of progenitor cells. Am. J. Physiol. Lung Cell Mol. Physiol. 286:L668-L678.
6. Frid, M.G., Kale, V.A., and Stenmark, K.R. 2002. Mature vascular endothelium can give rise to smooth muscle cells via endothelial-mesenchymal transdifferentiation: in vitro analysis. Circ. Res. 90:1189-1196.
7. Meyrick, B., Clarke, S.W., Symons, C., Woodgate, D.J., and Reid, L. 1974. Primary pulmonary hypertension: a case report including electronmicroscopic study. Br. J. Dis. Chest. 68:11-20.
8. Rabinovitch, M., et al. 1986. Pulmonary artery endothelial abnormalities in patients with congenital heart defects and pulmonary hypertension: A correlation of light with scanning electron microscopy and transmission electron microscopy. Lab. Invest. 55:632-653.
9. Rosenberg, H.C., and Rabinovitch, M. 1988. Endothelial injury and vascular reactivity in mono-crotaline pulmonary hypertension. Am. J. Physiol. 255:H1484-H1491.
10. Thompson, K., and Rabinovitch, M. 1996. Exogenous leukocyte and endogenous elastases can mediate mitogenic activity in pulmonary artery smooth muscle cells by release of extracellular-matrix bound basic fibroblast growth factor. J. Cell Physiol. 166:495-505.
11. Dewachter, L., et al. 2006. Angiopoietin/Tie2 pathway influences smooth muscle hyperplasia in idiopathic pulmonary hypertension. Am. J. Respir. Crit. Care Med. 174:1025-1033.
12. Taraseviciene-Stewart, L., et al. 2002. Abradykinin antagonist and a caspase inhibitor prevent severe pulmonary hypertension in a rat model. Can. J. Physiol. Pharmacol. 80:269-274.
13. Masri, F.A., et al. 2007. Hyperproliferative apoptosis-resistant endothelial cells in idiopathic pulmonary arterial hypertension. Am. J. Physiol. Lung Cell Mol. Physiol. 293:L548-L554.
14. Xu, W., et al. 2004. Increased arginase II and decreased NO synthesis in endothelial cells of patients with pulmonary arterial hypertension. FASEB J. 18:1746-1748.
15. Xu, W., et al. 2007. Alterations of cellular bioenergetics in pulmonary artery endothelial cells. Proc. Natl. Acad. Sci. U. S. A. 104:1342-1347
16. Chazova, I., et al. 1995. Pulmonary artery adventitial changes and venous involvement in primary pulmonary hypertension. Am. J. Pathol. 146:389-397
17. Jones, P., Cowan, K., and Rabinovitch, M. 1997. Progressive pulmonary vascular disease is characterized by a proliferative response related to deposition of tenascin-C and is preceded by subendo-thelial accumulation of fibronectin. Am. J. Pathol. 150:1349-1360.
18. Liptay, M.J., et al. 1993. Neointimal macrophages colocalize with extracellular matrix gene expression in human atherosclerotic pulmonary arteries. J. Clin. Invest. 91:588-594.
19. Greenway, S., et al. 2004. S100A4/Mts1 produces murine pulmonary artery changes resembling plexogenic arteriopathy and is increased in human plexogenic arteriopathy. Am. J. Pathol. 164:253-262.
20. Balabanian, K., et al. 2002. CX(3)C chemokine fractalkine in pulmonary arterial hypertension. Am. J. Respir. Crit. Care Med. 165:1419-1425.
21. Christman, B.W., et al. 1992. An imbalance between the excretion of thromboxane and prostacyclin metabolites in pulmonary hypertension. N. Engl J. Med. 327:70-75.
22. Barst, R.J., et al. 1996. A comparison of continuous intravenous epoprostenol (prostacyclin) with conventional therapy for primary pulmonary hypertension. The Primary Pulmonary Hypertension Study Group. N. Engl J. Med. 334:296-301.
23. Macchia, A., et al. 2007. A meta-analysis of trials of pulmonary hypertension: a clinical condition looking for drugs and research methodology. Am. Heart J. 153:1037-1047
24. Rich, S. 2007. The value of approved therapies for pulmonary arterial hypertension. Am. Heart J. 153:889-890.
25. Li, H., et al. 1994. Enhanced endothelin-1 and endothelin receptor gene expression in chronic hypoxia. J. Appl. Physiol. 77:1451-1459.
26. Giaid, A., et al. 1993. Expression of endothelin-1 in the lungs of patients with pulmonary hypertension. New Engl J. Med. 328:1732-1739.
27. Sitbon, O., et al. 2003. Effects of the dual endothelin receptor antagonist bosentan in patients with pulmonary arterial hypertension: a 1-year follow-up study. Chest. 124:247-254.
28. Barst, R.J., et al. 2004. Sitaxsentan therapy for pulmonary arterial hypertension. Am. J. Respir. Crit. Care Med. 169:441-447
29. Giaid, A., and Saleh, D. 1995. Reduced expression of endothelial nitric oxide synthase in the lungs of patients with pulmonary hypertension. New Engl J. Med. 333:214-221.
30. Humpl, T., Reyes, J.T., Holtby, H., Stephens, D., and Adatia, I. 2005. Beneficial effect of oral sildenafil therapy on childhood pulmonary arterial hypertension: twelve-month clinical trial of a single-drug, open-label, pilot study. Circulation. 111:3274-3280.
31. Hayakawa, I., et al. 2005. Successful treatment with sildenafil in systemic sclerosis patients with isolated pulmonary arterial hypertension: two case reports. Rheumatol Int. 26:270-273.
32. Juliana, A.E., and Abbad, F.C. 2005. Severe persistent pulmonary hypertension of the newborn in a setting where limited resources exclude the use of inhaled nitric oxide: successful treatment with sildenafil. Eur J. Pediatr. 164:626-629.
33. Machado, R.F., et al. 2005. Sildenafil therapy in patients with sickle cell disease and pulmonary hypertension. Br. J. Haematol. 130:445-453.
34. Dias-Junior, C.A., et al. 2005. The effect of sildenafil on pulmonary embolism-induced oxidative stress and pulmonary hypertension. Anesth. Analg 101:115-120.
35. Kataoka, M., et al. 2005. Oral sildenafil improves primary pulmonary hypertension refractory to epoprostenol. Circ. J. 69:461-465.
36. Wilkins, M.R., et al. 2005. Sildenafil versus endothelin receptor antagonist for pulmonary hypertension (SERAPH) study. Am. J. Respir. Crit. Care Med. 171:1292-1297.
37. Thenappan, T., Shah, S.J., Rich, S., and Gomberg-Maitland, M. 2007. A USA-based registry for pulmonary arterial hypertension:1982-2006. Eur. Respir. J. 30:1103-1110.
38. Nagaya, N., Mori, H., Murakami, S., Kangawa, K., and Kitamura, S. 2005. Adrenomedullin: angiogenesis and gene therapy. Am. J. Physiol. Regul Integr. Comp. Physiol. 288:R1432-R1437.
39. Said, S.I., et al. 2007. Moderate pulmonary arterial hypertension in male mice lacking the vasoactive intestinal peptide gene. Circulation. 115:1260-1268.
40. O'Blenes, S.B., Fischer, S., McIntyre, B., Keshavjee, S., and Rabinovitch, M. 2001. Hemodynamic unloading leads to regression of pulmonary vascular disease in rats. J. Thorac. Cardiovasc. Surg. 121:279-289.
41. Deb, S., et al. 2006. Reversal of idiopathic pulmonary arterial hypertension and allograft pneumonectomy after single lung transplantation. Chest. 130:214-217
42. Nishimura, T., et al. 2001. 40-O-(2-hydroxyethyl)-rapamycin attenuates pulmonary arterial hypertension and neointimal formation in rats. Am. J. Respir. Crit. Care Med. 163:498-502.
43. Oka, M., et al. 2007. Rho kinase-mediated vasoconstriction is important in severe occlusive pulmonary arterial hypertension in rats. Circ. Res. 100:923-929.
44. Ishikura, K., et al. 2006. Beneficial acute effects of rho-kinase inhibitor in patients with pulmonary arterial hypertension. Circ. J. 70:174-178.
45. Lane, K.B., et al. 2000. Heterozygous germline mutations in BMPR2, encoding a TGF-beta receptor, cause familial primary pulmonary hypertension. Nat. Genet. 26:81-84.
46. Deng, Z., et al. 2000. Familial primary pulmonary hypertension (gene PPH1) is caused by mutations in the bone morphogenetic protein receptor-II gene. Am. J. Hum. Genet. 67:737-744.
47. Rudarakanchana, N., et al. 2002. Functional analysis of bone morphogenetic protein type II receptor mutations underlying primary pulmonary hypertension. Hum. Mol Genet. 11:1517-1525.
48. Nohe, A., et al. 2002. The mode of bone morphogenetic protein (BMP) receptor oligomerization determines different BMP-2 signaling pathways. J. Biol. Chem. 277:5330-5338.
49. Grijelmo, C, et al. 2007. Proinvasive activity of BMP-7 through SMAD4/src-independent and ERK/Rac/JNK-dependent signaling pathways in colon cancer cells. Cell Signal. 19:1722-1732.
50. Tian, Q., He, X.C., Hood, L., and Li, L. 2005. Bridging the BMP and Wnt pathways by PI3 kinase/Akt and 14-3-3zeta. Cell Cycle. 4:215-216.
51. Roberts, K.E., et al. 2004. BMPR2 mutations in pulmonary arterial hypertension with congenital heart disease. Eur Respir. J. 24:371-374.
52. Humbert, M., et al. 2002. BMPR2 germline mutations in pulmonary hypertension associated with fenfluramine derivatives. Eur Respir. J. 20:518-523.
53. Atkinson, C, et al. 2002. Primary pulmonary hypertension is associated with reduced pulmonary vascular expression of type II bone morphogenetic protein receptor. Circulation. 105:1627-16787.
54. Du, L., et al. 2003. Signaling molecules in nonfamilial pulmonary hypertension. N. Engl J. Med. 348:500-509.
55. Teichert-Kuliszewska, K., et al. 2006. Bone morphogenetic protein receptor-2 signaling promotes pulmonary arterial endothelial cell survival: implications for loss-of-function mutations in the pathogenesis of pulmonary hypertension. Circ. Res. 98:209-217.
56. Morrell, N.W., et al. 2001. Altered growth responses of pulmonary artery smooth muscle cells from patients with primary pulmonary hypertension to transforming growth factor-beta(1) and bone morphogenetic proteins. Circulation. 104:790-795.
57. Zhang, S., et al. 2003. Bone morphogenetic proteins induce apoptosis in human pulmonary vascular smooth muscle cells. Am. J. Physiol. Lung Cell Mol. Physiol. 285:L740-L754.
58. Hansmann, G., et al. 2008. An antiproliferative BMP-2/PPARgamma/apoE axis in human and murine SMCs and its role in pulmonary hypertension. J. Clin. Invest. 118:1846-1857.
59. Jones, P., Crack, J., and Rabinovitch, M. 1997. Regulation of tenascin-C, a vascular smooth muscle cell survival factor that interacts with the αvβ3 integrin to promote epidermal growth factor receptor phosphorylation and growth. J. Cell Biol. 139:279-293.
60. Merklinger, S.L., Jones, P.L., Martinez, E.C., and Rabinovitch, M. 2005. Epidermal growth factor receptor blockade mediates smooth muscle cell apoptosis and improves survival in rats with pulmonary hypertension. Circulation. 112:423-431.
61. Beppu, H., et al. 2004. BMPR-II heterozygous mice have mild pulmonary hypertension and an impaired pulmonary vascular remodeling response to prolonged hypoxia. Am. J. Physiol. Lung Cell Mol Physiol. 287:L1241-L1247.
62. West, J., et al. 2004. Pulmonary hypertension in transgenic mice expressing a dominant-negative BMPRII gene in smooth muscle. Circ. Res. 94:1109-1114.
63. Nishimura, T., et al. 2003. Simvastatin rescues rats from fatal pulmonary hypertension by inducing apoptosis of neointimal smooth muscle cells. Circulation. 108:1640-1645.
64. McMurtry, M.S., et al. 2007. Overexpression of human bone morphogenetic protein receptor 2 does not ameliorate monocrotaline pulmonary arterial hypertension. Am. J. Physiol. Lung Cell Mol Physiol. 292:L872- L878.
65. Jeffery, T.K., Upton, P.D., Trembath, R.C., and Morrell, N.W. 2005. BMP4 inhibits proliferation and promotes myocyte differentiation of lung fibroblasts via Smad1 and JNK pathways. Am. J. Physiol Lung Cell Mol Physiol. 288:L370-L378.
66. Yang, X.,et al. 2005. Dysfunctional Smad signaling contributes to abnormal smooth muscle cell proliferation in familial pulmonary arterial hypertension. Circ. Res. 96:1053-1063.
67. Frank, D.B., et al. 2005. Bone morphogenetic protein 4 promotes pulmonary vascular remodeling in hypoxic pulmonary hypertension. Circ. Res. 97:496-504.
68. Yu, P.B., Beppu, H., Kawai, N., Li, E., and Bloch, K.D. 2005. Bone morphogenetic protein (BMP) type II receptor deletion reveals BMP ligand-specific gain of signaling in pulmonary artery smooth muscle cells. J. Biol. Chem. 280:24443-24450.
69. El-Bizri, N., et al. 2008. Smooth muscle protein 22alpha-mediated patchy deletion of Bmprla impairs cardiac contractility but protects against pulmonary vascular remodeling. Circ. Res. 102:380-388.
70. Harrison, R.E., et al. 2003. Molecular and functional analysis identifies ALK-1 as the predominant cause of pulmonary hypertension related to hereditary haemorrhagic telangiectasia. J. Med. Genet. 40:865-871.
71. Chaouat, A., et al. 2004. Endoglin germline mutation in a patient with hereditary haemorrhagic telangiectasia and dexfenfluramine associated pulmonary arterial hypertension. Thorax. 59:446-448.
72. Yeager, M.E., Halley, G.R., Golpon, H.A., Voelkel, N.F., andTuder, R.M. 2001. Microsatellite instability of endothelial cell growth and apoptosis genes within plexiform lesions in primary pulmonary hypertension. Circ. Res. 88:E2-E11.
73. Morrell, N.W. 2006. Pulmonary hypertension due to BMPR2 mutation: a new paradigm for tissue remodeling? Proc. Am. Thorac. Soc. 3:680-686.
74. Wu, X., Chang, M.S., Mitsialis, S.A., and Kourem-banas, S. 2006. Hypoxia regulates bone morphogenetic protein signaling through C-terminal-binding protein 1. Circ. Res. 99:240-247.
75. Crossno, J.T., Jr., et al. 2007. Rosiglitazone attenuates hypoxia-induced pulmonary arterial remodeling. Am. J. Physiol. Lung Cell Mol. Physiol. 292:L885-L897.
76. Hansmann, G., et al. 2007. Pulmonary arterial hypertension is linked to insulin resistance and reversed by peroxisome proliferator-activated receptor-gamma activation. Circulation. 115:1275-1284.
77. Takayama, Y., May, P., Anderson, R.G., and Herz, J. 2005. Low density lipoprotein receptor-related protein 1 (LRP1) controls endocytosis and c-CBL-mediated ubiquitination of the platelet-derived growth factor receptor beta (PDGFRbeta). J. Biol Chem. 280:18504-18510.
78. Schermuly, R.T., et al. 2005. Reversal of experimental pulmonary hypertension by PDGF inhibition. J. Clin. Invest. 115:2811-2821.
79. Ghofrani, H.A., Seeger, W., and Grimminger, F. 2005. Imatinib for the treatment of pulmonary arterial hypertension. N. Engl J. Med. 353:1412-1413.
80. Arita, Y., et al. 2002. Adipocyte-derived plasma protein adiponectin acts as a platelet-derived growth factor-BB-binding protein and regulates growth factor-induced common postreceptor signal in vascular smooth muscle cell. Circulation. 105:2893-2898.
81. Wigle, D.A., et al. 1998. AML1-like transcription factor induces serine elastase activity in ovine pulmonary artery smooth muscle cells. Circ. Res. 83:252-263.
82. Lawrie, A., et al. 2008. Evidence of a role for osteo-protegerin in the pathogenesis of pulmonary arterial hypertension. Am. J. Pathol. 172:256-264.
83. Ihida-Stansbury, K., et al. 2006. Tenascin-C is induced by mutated BMP type II receptors in familial forms of pulmonary arterial hypertension. Am. J. Physiol. Lung Cell Mol. Physiol. 291:L694-L702.
84. Todorovich-Hunter, L., et al. 1992. Increased pulmonary artery elastolytic activity in adult rats with monocrotaline-induced progressive hypertensive pulmonary vascular disease compared with infant rats with nonprogressive disease. Am. Rev. Respir. Dis. 146:213-223.
85. Ye, C., and Rabinovitch, M. 1991. Inhibition of elastolysis by SC-37698 reduces development and progression of monocrotaline pulmonary hypertension. Am. J. Physiol. 261:H1255-H1267.
86. Maruyama, K., et al. 1991. Chronic hypoxic pulmonary hypertension in rats and increased elastolytic activity. Am. J. Physiol. 261:H1716- H1726.
87. Cowan, K.N., et al. 2000. Complete reversal of fatal pulmonary hypertension in rats by a serine elastase inhibitor. Nat. Med. 6:698-702.
88. McMurtry, M.S., et al. 2005. Gene therapy targeting survivin selectively induces pulmonary vascular apoptosis and reverses pulmonary arterial hypertension. J. Clin. Invest. 115:1479-1491.
89. Fantozzi, I., et al. 2006. Bone morphogenetic protein-2 upregulates expression and function of voltage-gated K+ channels in human pulmonary artery smooth muscle cells. Am. J. Physiol. Lung Cell Mol. Physiol. 291:L993-L1004.
90. Michelakis, E.D., et al. 2002. Dichloroacetate, a metabolic modulator, prevents and reverses chronic hypoxic pulmonary hypertension in rats: role of increased expression and activity of voltage-gated potassium channels. Circulation. 105:244-250.
91. McMurtry, M.S., et al. 2004. Dichloroacetate prevents and reverses pulmonary hypertension by inducing pulmonary artery smooth muscle cell apoptosis. Circ. Res. 95:830-840.
92. Bonnet, S., et al. 2006. An abnormal mitochondrial-hypoxia inducible factor-1alpha-Kv channel pathway disrupts oxygen sensing and triggers pulmonary arterial hypertension in fawn hooded rats: similarities to human pulmonary arterial hypertension. Circulation. 113:2630-2641.
93. Cogolludo, A., et al. 2006. Serotonin inhibits voltage-gated K+ currents in pulmonary artery smooth muscle cells: role of 5-HT2A receptors, caveolin-1, and KV1.5 channel internalization. Circ. Res. 98:931-938.
94. Yu, Y., et al. 2004. Enhanced expression of transient receptor potential channels in idiopathic pulmonary arterial hypertension. Proc. Natl. Acad. Sci. U. S. A. 101:13861-13866.
95. Zhang, S., et al. 2007. Pulmonary artery smooth muscle cells from normal subjects and IPAH patients show divergent cAMP-mediated effects on TRPC expression and capacitative Ca2+ entry. Am. J. Physiol. Lung Cell Mol. Physiol. 292:L1202-L1210.
96. Le Cras, T.D., Kim, D.H., Markham, N.E., and Abman, A.S. 2000. Early abnormalities of pulmonary vascular development in the Fawn-Hooded rat raised at Denver's altitude. Am. J. Physiol. Lung Cell Mol. Physiol. 279:L283-L291.
97. Eddahibi, S., et al. 2000. Attenuated hypoxic pulmonary hypertension in mice lacking the 5-hydroxytryptamine transporter gene. J. Clin. Invest. 105:1555-1562.
98. MacLean, M.R., et al. 2004. Overexpression of the 5-hydroxytryptamine transporter gene: effect on pulmonary hemodynamics and hypoxia-induced pulmonary hypertension. Circulation. 109:2150-2155.
99. Guignabert, C, et al. 2006. Transgenic mice over-expressing the 5-hydroxytryptamine transporter gene in smooth muscle develop pulmonary hypertension. Circ. Res. 98:1323-1330.
100. Long, L., et al. 2006. Serotonin increases susceptibility to pulmonary hypertension in BMPR2-deficientmice. Circ. Res. 98:818-827.
101. Liu, Y, Li, M., Warburton, R.R., Hill, N.S., and Fanburg, B.L. 2007. The 5-HT transporter transactivates the PDGF{beta} receptor in pulmonary artery smooth muscle cells. FASEB J. 21:2725-2734.
102. Suzuki, Y.J., et al. 2003. Activation of GATA-4 by serotonin in pulmonary artery smooth muscle cells. J. Biol. Chem. 278:17525-17531.
103. Simon, A.R., et al. 2005. 5-HT induction of c-fos gene expression requires reactive oxygen species and Rac1 and Ras GTPases. Cell Bio chem. Biophys. 42:263-276.
104. Lawrie, A., et al. 2005. Interdependent serotonin transporter and receptor pathways regulate S100A4/Mts1, a gene associated with pulmonary vascular disease. Circ. Res. 97:227-235.
105. Eddahibi, S., et al. 2003. Polymorphism of the serotonin transporter gene and pulmonary hypertension in chronic obstructive pulmonary disease. Circulation. 108:1839-1844.
106. Morse, J.H., et al. 1996. Primary pulmonary hypertension in HIV infection: an outcome determined by particular HLA class II alleles. Am. J. Respir. Crit. Care Med. 153:1299-1301.
107. Cool, CD., et al. 2003. Expression of human herpesvirus 8 in primary pulmonary hypertension. N. Engl. J. Med. 349:1113-1122.
108. Spiekerkoetter, E., et al. 2008. Reactivation of gammaHV68 induces neointimal lesions in pulmonary arteries of S100A4/Mts1-overexpressing mice in association with degradation of elastin. Am. J. Physiol. Lung Cell Mol. Physiol. 294:L276-L289.
109. Marecki,J.C., et al. 2006. HIV-1 Nefis associated with complex pulmonary vascular lesions in SHIV-nef-infected macaques. Am. J. Respir. Crit. Care Med. 174:437-445.
110. Daley, E., et al. 2008. Pulmonary arterial remodeling induced by a Th2 immune response. J. Exp. Med. 205:361-372.
111. Ulanet, D.B., Flavahan, N.A., Casciola-Rosen, L., and Rosen, A. 2004. Selective cleavage of nucleolar autoantigen B23 by granzyme B in differentiated vascular smooth muscle cells: insights into the association of specific autoantibodies with distinct disease phenotypes. Arthritis Rheum. 50:233-241.
112. Song, Y., et al. 2005. Increased susceptibility to pulmonary hypertension in heterozygous BMPR2-mutantmice. Circulation. 112:553-562.
113. Meyrick, B.,and Brigham, K. 1986. Repeated eschrerichia coli endotocin-induced pulmonary inflammation causes chronic pulmonary hypertension in sheep. Lab. Invest. 55:164-176.
114. Stevens, T., Janssen, P.L., and Tucker, A.D. 1992. Acute and long-term TNF-alpha administration increases pulmonary vascular reactivity in isolated rat lungs. J. Appl. Physiol. 73:708-712.
115. Taraseviciene-Stewart, L., et al. 2007. Absence of T cells confers increased pulmonary arterial hypertension and vascular remodeling. Am. J. Respir. Crit. Care Med. 175:1280-1289.
116. Perros, F., et al. 2007. Fractalkine-induced smooth muscle cell proliferation in pulmonary hypertension. Eur Respir. J. 29:937-943.
117. Hagen, M., et al. 2007. Interaction of interleukin-6 and the BMP pathway in pulmonary smooth muscle. Am. J. Physiol. Lung Cell Mol. Physiol. 292:L1473-L1479.
118. Bonnet, S., et al. 2007. The nuclear factor of activated T cells in pulmonary arterial hypertension can be therapeutically targeted. Proc. Natl. Acad. Sci. U. S. A. 104:11418-11423.
119. Baber, S.R., et al. 2006. Intratracheal mesenchymal stem cell administration attenuates monocrotaline-induced pulmonary hypertension and endothelial dysfunction. Am. J. Physiol. Heart Circ. Physiol. 292:H1120-H1128.
120. Deng, W., et al. 2006. Inhibition of vascular smooth muscle cell proliferation in vitro by genetically engineered marrow stromal cells secreting calcitonin gene-related peptide. Life Sci. 78:1830-1838.
121. Kanki-Horimoto, S., et al. 2006. Implantation of mesenchymal stem cells overexpressing endothelial nitric oxide synthase improves right ventricular impairments caused by pulmonary hypertension. Circulation. 114:I181-I185.
122. Zhao, Y.D., et al. 2005. Rescue of monocrotaline-induced pulmonary arterial hypertension using bone marrow-derived endothelial-like progenitor cells: efficacy of combined cell and eNOS gene therapy in established disease. Circ. Res. 96:442-450.
123. Wang, X.X., et al. 2007. Transplantation of autologous endothelial progenitor cells may be beneficial in patients with idiopathic pulmonary arterial hypertension: a pilot randomized controlled trial. J. Am. Coll. Cardiol. 49:1566-1571.
124. Weinberg, C.E., et al. 2004. Extraction of pulmonary vascular compliance, pulmonary vascular resistance, and right ventricular work from single-pressure and Doppler flow measurements in children with pulmonary hypertension: a new method for evaluating reactivity: in vitro and clinical studies. Circulation. 110:2609-2617.
125. Mahmud, M., and Champion, H.C. 2007. Right ventricular failure complicating heart failure: pathophysiology, significance, and management strategies. Curr. Cardiol. Rep. 9:200-208.